Pharmaceuticals & Therapeutics

Medtech firm TELA Bio overhauls its board with M&A and turnaround experts, signaling a major strategic shift to accelerate growth and escape losses.

Eli Lilly begins a crucial Phase 2 study for a novel, non-addictive pain drug from Confo Therapeutics, a major step in the hunt for an opioid alternative.

PVP Labs' new drug offers potent pain relief without addiction risk. A landmark DEA ruling clears it as a non-controlled substance, set to reshape medicine.

Wellspect HealthCare's new Surity™ catheter targets a growing market, offering a non-invasive solution designed for comfort, discretion, and dignity.

A new imaging agent could slash the years-long diagnostic delay for endometriosis, offering hope to millions of women suffering from the debilitating condition.

Swiss medtech firm CorFlow is tackling a major post-heart attack complication with two pivotal trials, aiming to create a new standard of care.

Former HHS Secretary Tommy Thompson joins Vector Science & Therapeutics, leveraging his political clout to advance a novel transdermal drug delivery platform.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

After a turbulent year, Valerio Therapeutics unveils a radical new strategy focused on its V-Body platform, a new subsidiary, and strict cost controls.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

As AI accelerates drug approvals, a new bottleneck emerges. Firms like Totaligent are betting on the infrastructure needed to get therapies to patients.

With a new General Counsel known for navigating complex deals, Cosette Pharmaceuticals signals a major push for acquisitions and portfolio growth.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

Once a hospital disinfectant, hypochlorous acid is now a skincare star. Magic Molecule's massive CVS launch signals a major shift in the beauty industry.

Italian biopharma giant Chiesi makes its largest acquisition ever, targeting KalVista's groundbreaking oral HAE drug to reshape patient care and its future.

KCIC's 2025 report shows asbestos filings hitting a new peak, driven by a dramatic rise in talc-related lawsuits and massive jury awards.

Shanghai's Vivacta Bio raises over $50M from top VCs to revolutionize cancer treatment with its pioneering in vivo CAR-T therapy, GT801.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

A new patent for a biomarker-guided therapy offers hope for millions with treatment-resistant depression and extends market exclusivity for decades.